We have conducted a prospective pilot study to determine the efficacy and safety of neoadjuvant radiotherapy followed by dalpiciclib and exemestane in patients with newly diagnosed early or locally advanced HR-positive, HER2-negative breast cancer. Here, ERBB2 is linked to breast carcinoma.